Premium
La Pentamidina como profilaxis secundaria para la leishmaniasis visceral en hospederos inmunocomprometidos: reporte de cuatro casos
Author(s) -
Patel T. A.,
Lockwood D. N.
Publication year - 2009
Publication title -
tropical medicine and international health
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.056
H-Index - 114
eISSN - 1365-3156
pISSN - 1360-2276
DOI - 10.1111/j.1365-3156.2009.02329.x
Subject(s) - pentamidine , medicine , visceral leishmaniasis , observational study , leishmaniasis , pediatrics , retrospective cohort study , surgery , immunology , pneumonia
Summary We report a retrospective and descriptive study of four immunocompromised patients (three with HIV‐1 and one with idiopathic CD4+‐lymphopenia) with relapsing visceral leishmaniasis seen at the Hospital for Tropical Diseases, London, in whom pentamidine was used as secondary prophylaxis to prevent relapse. Patients experienced between one and four relapses before commencing prophylaxis with subsequent relapse‐free periods ranging from 5 to 98 months. Based on these observational data, we recommend large trials to investigate the efficacy of pentamidine over other agents in preventing relapse of VL in the immunocompromised patient.